Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2007 / Cilt: 17 - Sayı: 2

Pancreatic non hodgkin lymphoma: Case report

Pankreatik non-hodgkin lenfoma vakası

Pages
108–111
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When evaluating pancreatic tumors, the possibility of lymphoma should be kept in mind.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Extranodal non-Hodgkin's lymphoma generally involves the stomach and intestinal tract.
📊
Key Findings & Data:Cyclophosphamide, doxorubicin, vincristine, prednisolone, and anti-CD20 Antibody (rituximab) chemotherapy regimen was started.
💡
Conclusion & Impact:When evaluating pancreatic tumors, the possibility of lymphoma should be kept in mind.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Pankreas hastalıkları · Orta yaşlı · Erkek

Abstract

Extranodal non-Hodgkin's lymphoma generally involves the stomach and intestinal tract. The majority of pancreas tumors are adenocarcinomas but rarely, lymphomas are also reported. It is difficult to distinguish pancreatic lymphoma from adenocarcinoma by clinical or radiologic assessment. The patient is a fifty nine year old man was admitted to the hospital with abdominal pain, a mass in the head of the pancreas and peripancreatic lymphadenopathy. The biopsy, which was done from the mass in the head of the pancreas, revealed diffuse large B cell non-Hodgkin's lymphoma. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and anti-CD20 Antibody (rituximab) chemotherapy regimen was started. While lymphomas of the pancreas are rare, the prognosis and treatment differ dramatically from that of adenocarcinomas. When evaluating pancreatic tumors, the possibility of lymphoma should be kept in mind.

Özet

Ekstranodal non-Hodgkin lenfoma, mide ve bağırsak sistemini sıkça tutmaktadır. Pankreasın malign tümörleri büyük oranda adenokarsinoma yapısında olup nadir olarak lenfoma da bildirilmiştir. Pankreatik lenfomaların klinik ve radyolojik olarak adenokanserlerden ayırt edilmesi zordur. Karın ağrısı nedeni ile başvuran elli dokuz yaşında erkek hastanın yapılan değerlendirmesinde; pankreas başında kitle ve çevresinde büyümüş lenfadenopatiler tespit edildi. Kitleden yapılan biopsi sonucunda diffuz büyük B hücreli non Hodgkin lenfoma tanısı kondu. Siklofosfamid, adriamisin, vinkristin, prednisolon (CHOP) ve anti-CD20-antikor (rituximab) kemoterapisi başlandı. Pankreas yerleşimli tümörlerde, adenokanserlerden prognoz ve tedavisi dramatik olarak farklı olan lenfoma olasılığı akılda tutulmalıdır.

🔖

Cite This Article

ÇELENKOĞLU, G., UTKAN, G., IRKKAN, Ç., BENZER, E., ARSLAN, Ü. Y., TOKLUOĞLU, S., MUALLAOĞLU, S., KOÇER, M., ALKIŞ, N. (2007). Pancreatic non hodgkin lymphoma: Case report. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 17 - Sayı: 2, 108–111. https://ajindex.com/articles/323035

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Ji Y, Kuang TT, Tan YS, et al. Pancreatic primary lymphoma: a case report and review of the literature. Hepatobiliary Pancreat Dis Int 4:622- 626, 2005
  2. Boni L, Benevento A, Dionigi G et al. Primary pancreatic lymphoma. Surg Endosc 16:1107- 1108, 2002 3. Nakamura E, Shimizu M, Itoh T, Manabe T. Secondary tumors of the pancreas: Clinicopathological study of 103 autopsy cases of Japanese patients. Pathol Int 51:686-690, 2001
  3. Mofredj A, Cadranel JF, Cazier A, et al.Malignant pancreatic non-hodgkin's lymphoma manifesting as severe acute pancreatitis. Gastroenterol Clin Biol 23:528-531, 1999
  4. Ueda K, Nagayama Y, Narita K et al. Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg 7:610-613, 2000
  5. Prayer L, Schurawitzki H, Mallek R, Mostbeck G. CT in pancreatic involvement of non-Hodgkin lymphoma. Acta Radiol 33:123-127, 1992
  6. Tondini C, Giardini R, Bozzetti F et al. Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. Ann Oncol 4:831-837, 1993.